No Data
Express News | The Cash Component Of The Aggregate Merger Consideration Will Be A Base Cash Amount Of $9,005,000 (Consisting Of A Value Of $15M Minus The $5,995,000 Advanced To Kineta Under The Exclusivity And Right Of First Offer Agreement)
Kineta Merges With TuHURA to Enhance Cancer Treatment
TuHURA Biosciences To Acquire Kineta, Cash Component Of Merger Consideration Will Be Base Cash Amount Of $9,005,000 Less The Sum Of Kineta's Working Capital Deficit At Closing; In Connection With Merger, TuHURA And Kineta Entered Clinical Trial...
Express News | Tuhura Biosciences Inc: Enters Into Definitive Merger Agreement to Acquire Kineta, Inc.
Kineta and TuHURA Enter Acquisition Agreement
Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 VISTA101 Study
No Data
